Roc-SpA study Active axSpA dse + inad response to TNFi ➡️switch or cycled No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi Shared decision is key AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv

• https://x.com/RHEUMarampa/status/2062438779202261286/photo/1

#OP0236: a look at the revised 2025 ASAS-SPARTAN classification criteria for axSpA from the global CLASSIC cohort. The updated criteria achieved 79.5% sensitivity & 90.4% specificity, with MRI & radiographic sacroiliitis remaining central to classification. #EULAR2026 @RheumNow https://t.co/rVIqyCmB8K

• https://x.com/DrMiniDey/status/2062478467053326595/photo/1

Is there a ‘window Of opportunity’ for Rx #GCA w #IL6i 🤞 Obtain a better response Rx GCA #GC #TCZ #Upadacitinib #MTX Study tries to answer if effects of #tocilizumab early vs >8wks is diff N=471, 19% new GCA Early vs late TCZ no dif ❎No Not RCT POS0624 #EULAR2026 @RheumNow

And we are on! A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos @RheumNow https://t.co/zTQUFcjXBI

• https://x.com/AurelieRheumo/status/2062149444317917227/photo/1

It’s that time of year again! 🎉 Delighted to once again be joining the @RheumNow faculty to bring you the highlights from #EULAR2026 in London! @bella_mehta @JihaRheum @AurelieRheumo @Janetbirdope @Nellziade @RHEUMarampa @synovialjoints @Yuz6Yusof https://t.co/WvhpYJJNUk

• https://x.com/DrMiniDey/status/2062137562404118884/photo/1

"the further I look back, the further I can see the future" Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026 @eular_org @RheumNow https://t.co/ayInzzb9lO

• https://x.com/AurelieRheumo/status/2062164857076531604/photo/1

#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow https://t.co/ftx1uBP11A

• https://x.com/Yuz6Yusof/status/2062250917391397326/photo/1

🔍 Is #axSpA overdiagnosed locally? IMPROVE-axSpA prosp study (n=969): Yes! Only 54% locally confirmed centrally #OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB

• https://x.com/Nellziade/status/2062241054779195511/photo/1

💉 IXE+TZP beat IXE alone in obese PsA? YES - TOGETHER-PsA RCT 33.5% vs 20.4% ACR50 at week 36 in 271 patients OP069 #EULAR2026 @RheumNow @DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc

• https://x.com/Nellziade/status/2062241947532546238/photo/1

The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn

• Home | RheumNow

🔍 What defines a positive MRI for #axSpA? SPARTAN-SSR consensus (n=1,050): BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants #OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm

• https://x.com/Nellziade/status/2062239875663908892/photo/1

#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow